Supplementary Figure 7 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study | AMiner
Supplementary Figure 7 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 7. Distribution of T cell subsets pre-treatment and post-treatment for high (Patients 7 and 6) and low (Patients 13 and 14) immune responders.
原文链接
分享
引用
